company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2250000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,55000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2305000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2305000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5680000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,291000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,874000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,10717000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17562000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-15257000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,16000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,16000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-15241000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-15241000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-15241000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-15241000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,32396000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.47
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,32396000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.47
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,32400000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:47:25+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.47
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1936000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,31000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1967000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1967000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5414000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,110000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,532000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,13029000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,19085000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-17118000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,17000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,17000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-17101000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-17101000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-17101000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-17101000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,32814000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.52
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,32814000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.52
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,32900000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:04:27+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.52
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2347000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,41000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2388000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2388000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5197000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,364000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,536000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,19236000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,25333000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-22945000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,18000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,18000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-22927000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-22927000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-22927000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-22927000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,33273000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,0.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.69
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,33273000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 17:18:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.69
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,74388000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,19000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,74407000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,88000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,88000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,74319000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4952000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13302000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,525000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,70000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18849000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,55470000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,16000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,16000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,55486000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,55486000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,55486000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,55486000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,33510000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.66
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,33787000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.64
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,33400000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:03:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.66
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5776000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,28000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5804000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,114000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,114000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5690000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4064000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12406000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,520000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,147000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17137000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11447000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,15000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,15000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11432000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11432000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11432000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11432000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,33710000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.34
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,33710000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.34
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,33710000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 15:15:01+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.34
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2109000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,88000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2197000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,376000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,376000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1821000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4035000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,27111000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,485000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-19048000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12583000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10762000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,16000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,16000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10746000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10746000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10746000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10746000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,33375000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.01
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,33494000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.3
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,33500000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2011.0,Q4,2011-10-01,2011-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.32
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2211000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,15000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2226000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,40000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,40000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2186000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3721000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10909000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,472000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,185000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15287000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13101000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,15000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,15000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-13086000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13086000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13086000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13086000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,33761000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.39
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,33761000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.39
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,33761000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 15:42:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.39
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1801000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,19000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1820000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,110000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,110000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1710000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4025000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7957000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,300000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,162000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12444000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10734000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,14000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,14000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10720000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10720000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10720000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10720000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,33798000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.32
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,33798000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.32
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,33798000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q2,2012-04-01,2012-06-30,2013-08-09 12:17:57+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.32
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1107000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,10000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1117000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,510000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,510000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,607000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4007000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7551000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,291000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,73000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11922000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11315000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,14000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,14000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11301000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11301000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11301000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11301000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,33848000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.33
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,33848000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.33
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,33848000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 09:54:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.33
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8857000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,28000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8885000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,510000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,510000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8375000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3461000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4915000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,261000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,79000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8716000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-341000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,17000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,17000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-324000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-324000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-324000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-324000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,34754000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.02
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,34754000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.02
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,34754000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.02
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2208000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,18000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2226000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,70000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,70000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2156000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4314000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8721000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,277000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,116000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13428000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11272000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,14000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,14000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11258000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11258000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11258000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11258000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,50116000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.22
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,50116000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.22
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,50116000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 10:40:43+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.22
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1767000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,34000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1801000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,153000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,153000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1648000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3899000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9585000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,318000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,119000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13921000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12273000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,10000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,10000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12263000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12263000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12263000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12263000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51481000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.24
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51481000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.24
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51481000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 14:01:06+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.24
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,864000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,3000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,867000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,91000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,91000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,776000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3131000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7905000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,179000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,73000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11288000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10512000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,12000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,12000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10500000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10500000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10500000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10500000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,60599000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,60599000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,60599000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:01+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2954000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,14000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2968000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,253000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,253000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2715000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3465000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7692000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,165000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,316000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11638000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-8923000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,10000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,10000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-8913000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-362000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-8551000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-8551000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-8551000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,55798000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.13
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,55798000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.13
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,55798000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.13
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1784000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,31000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1815000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,90000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,90000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1725000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3405000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6919000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,144000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,82000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,500000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11050000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9325000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,12000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,12000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9313000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9313000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9313000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9313000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,63958000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.15
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,63958000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.15
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,63958000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 14:32:58+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.15
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1439000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,38000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1477000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,180000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,180000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1297000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3856000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7848000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,133000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,147000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,400000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12384000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11087000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,13000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,13000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11074000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11073000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11073000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11073000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,69561000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.16
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,69561000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.16
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,69561000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:09:22+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.16
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,41649000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,7000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,41656000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,160000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,160000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,41496000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3895000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6728000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,142000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-7081000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,576000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,500000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,4760000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,36736000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,12000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,12000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,36748000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-227000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,36975000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,36975000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,36975000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,69556000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.53
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,72879000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.51
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,69800000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:12:10+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.53
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,-575000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,4000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,-571000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,-430000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,-430000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-141000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4333000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7097000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,-419000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-398000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,2100000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,100000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12813000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12954000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-37000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,51000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,14000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12940000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-761000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12179000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,4410000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7769000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7769000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,68185000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.16
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,68243000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.14
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,147000000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.16
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:32:00+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,239000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:32:00+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,9000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:32:00+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,248000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:32:00+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,248000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:32:00+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3725000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:32:00+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6489000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:32:00+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,300000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:32:00+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10514000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:32:00+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10266000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:32:00+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,12000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:32:00+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,12000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:32:00+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10254000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:32:00+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10254000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:32:00+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10254000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:32:00+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:32:00+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10254000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:32:00+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,68400000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:32:00+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.15
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:32:00+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,68400000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:32:00+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.15
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:32:00+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,69637000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:32:00+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.15
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:09:46+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1918000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:09:46+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,19000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:09:46+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1937000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:09:46+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1937000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:09:46+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6127000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:09:46+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6718000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:09:46+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,800000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:09:46+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13645000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:09:46+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11708000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:09:46+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,11000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:09:46+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,11000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:09:46+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11697000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:09:46+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11697000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:09:46+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11697000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:09:46+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:09:46+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11697000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:09:46+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,68800000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:09:46+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:09:46+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,68800000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:09:46+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:09:46+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,69647000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:09:46+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:37:49+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1391000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:37:49+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,5000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:37:49+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1396000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:37:49+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1396000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:37:49+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4572000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:37:49+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7048000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:37:49+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-200000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:37:49+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11420000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:37:49+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10024000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:37:49+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,10000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:37:49+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,10000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:37:49+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10014000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:37:49+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10014000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:37:49+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10014000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:37:49+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:37:49+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10014000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:37:49+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,69705000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:37:49+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.14
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:37:49+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,69705000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:37:49+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.14
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:37:49+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,71500000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 16:37:49+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.14
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5015000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,80000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5095000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5095000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3760000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7941000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,700000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12401000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7306000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,19000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,19000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7287000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-133000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7154000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7154000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-7000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7147000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,69800000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.1
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,69716000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.1
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,69716000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.1
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q1,2016-01-01,2016-03-31,2017-08-09 09:10:39+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8453000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q1,2016-01-01,2016-03-31,2017-08-09 09:10:39+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,23000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q1,2016-01-01,2016-03-31,2017-08-09 09:10:39+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8476000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q1,2016-01-01,2016-03-31,2017-08-09 09:10:39+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8476000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q1,2016-01-01,2016-03-31,2017-08-09 09:10:39+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5599000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q1,2016-01-01,2016-03-31,2017-08-09 09:10:39+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7988000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q1,2016-01-01,2016-03-31,2017-08-09 09:10:39+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,600000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q1,2016-01-01,2016-03-31,2017-08-09 09:10:39+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14187000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q1,2016-01-01,2016-03-31,2017-08-09 09:10:39+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5711000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q1,2016-01-01,2016-03-31,2017-08-09 09:10:39+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,54000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q1,2016-01-01,2016-03-31,2017-08-09 09:10:39+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,54000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q1,2016-01-01,2016-03-31,2017-08-09 09:10:39+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5657000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q1,2016-01-01,2016-03-31,2017-08-09 09:10:39+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5657000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q1,2016-01-01,2016-03-31,2017-08-09 09:10:39+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5657000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q1,2016-01-01,2016-03-31,2017-08-09 09:10:39+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-19000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q1,2016-01-01,2016-03-31,2017-08-09 09:10:39+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5638000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q1,2016-01-01,2016-03-31,2017-08-09 09:10:39+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,70500000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q1,2016-01-01,2016-03-31,2017-08-09 09:10:39+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.08
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q1,2016-01-01,2016-03-31,2017-08-09 09:10:39+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,70500000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q1,2016-01-01,2016-03-31,2017-08-09 09:10:39+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.08
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q1,2016-01-01,2016-03-31,2017-08-09 09:10:39+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,69947000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q1,2016-01-01,2016-03-31,2017-08-09 09:10:39+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.08
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:09:46+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8453000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:09:46+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,23000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:09:46+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8476000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:09:46+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8476000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:09:46+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5599000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:09:46+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7988000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:09:46+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,600000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:09:46+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14187000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:09:46+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5711000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:09:46+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,54000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:09:46+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,54000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:09:46+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5657000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:09:46+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5657000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:09:46+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5657000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:09:46+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-19000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:09:46+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5638000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:09:46+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,70500000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:09:46+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.08
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:09:46+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,70500000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:09:46+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.08
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:09:46+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,69947000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q2,2016-04-01,2016-06-30,2016-08-04 16:09:46+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.08
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:27:30+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,53842000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:27:30+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,8000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:27:30+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,53850000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:27:30+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,53850000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:27:30+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7220000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:27:30+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9827000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:27:30+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,600000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:27:30+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17647000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:27:30+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,36203000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:27:30+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,79000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:27:30+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,79000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:27:30+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,36282000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:27:30+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,36282000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:27:30+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,36282000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:27:30+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-21000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:27:30+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,36303000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:27:30+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,69800000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:27:30+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.52
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:27:30+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,70297000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:27:30+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.52
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:27:30+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,70013000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:27:30+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.52
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,-1319000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,-54000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,-1373000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-1373000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4938000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11766000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-6400000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10304000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11677000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-714000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-714000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12391000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1844000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14235000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14235000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-14000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14221000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,70003000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.21
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,70155000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.21
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,72000000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.21
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 16:02:01+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2347000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 16:02:01+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2347000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 16:02:01+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2347000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 16:02:01+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5695000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 16:02:01+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10005000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 16:02:01+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,1900000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 16:02:01+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17600000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 16:02:01+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-15253000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 16:02:01+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-1107000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 16:02:01+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1107000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 16:02:01+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-16360000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 16:02:01+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16360000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 16:02:01+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16360000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 16:02:01+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-16360000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 16:02:01+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,71100000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 16:02:01+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.23
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 16:02:01+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,71100000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 16:02:01+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.23
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 16:02:01+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,70196000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 16:02:01+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.23
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q2,2017-04-01,2017-06-30,2018-07-31 17:15:27+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2765000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q2,2017-04-01,2017-06-30,2018-07-31 17:15:27+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2765000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q2,2017-04-01,2017-06-30,2018-07-31 17:15:27+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2765000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q2,2017-04-01,2017-06-30,2018-07-31 17:15:27+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6333000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q2,2017-04-01,2017-06-30,2018-07-31 17:15:27+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11292000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q2,2017-04-01,2017-06-30,2018-07-31 17:15:27+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,700000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q2,2017-04-01,2017-06-30,2018-07-31 17:15:27+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18325000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q2,2017-04-01,2017-06-30,2018-07-31 17:15:27+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-15560000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q2,2017-04-01,2017-06-30,2018-07-31 17:15:27+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-1076000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q2,2017-04-01,2017-06-30,2018-07-31 17:15:27+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1076000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q2,2017-04-01,2017-06-30,2018-07-31 17:15:27+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-16636000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q2,2017-04-01,2017-06-30,2018-07-31 17:15:27+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q2,2017-04-01,2017-06-30,2018-07-31 17:15:27+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16636000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q2,2017-04-01,2017-06-30,2018-07-31 17:15:27+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16636000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q2,2017-04-01,2017-06-30,2018-07-31 17:15:27+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-16636000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q2,2017-04-01,2017-06-30,2018-07-31 17:15:27+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,69300000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q2,2017-04-01,2017-06-30,2018-07-31 17:15:27+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.24
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q2,2017-04-01,2017-06-30,2018-07-31 17:15:27+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,69300000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q2,2017-04-01,2017-06-30,2018-07-31 17:15:27+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.24
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q2,2017-04-01,2017-06-30,2018-07-31 17:15:27+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,70202000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q2,2017-04-01,2017-06-30,2018-07-31 17:15:27+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.24
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:01:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2697000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:01:56+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2697000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:01:56+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2697000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:01:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5958000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:01:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10344000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:01:56+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:01:56+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,700000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:01:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17002000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:01:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-14305000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:01:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-1047000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:01:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1047000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:01:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-15352000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:01:56+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:01:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-15352000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:01:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-15352000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:01:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-15352000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:01:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,69800000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:01:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.22
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:01:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,69800000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:01:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.22
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:01:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,70270000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:01:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.22
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3889000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3889000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3889000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6923000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10948000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-700000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17171000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13282000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-1055000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1055000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-14337000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-11672000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-2665000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-2665000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-2665000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,69900000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.04
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,69900000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.04
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,70284000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.04
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q1,2018-01-01,2018-03-31,2018-05-09 16:02:01+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3189000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q1,2018-01-01,2018-03-31,2018-05-09 16:02:01+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3189000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q1,2018-01-01,2018-03-31,2018-05-09 16:02:01+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3189000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q1,2018-01-01,2018-03-31,2018-05-09 16:02:01+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6697000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q1,2018-01-01,2018-03-31,2018-05-09 16:02:01+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8110000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q1,2018-01-01,2018-03-31,2018-05-09 16:02:01+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,800000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q1,2018-01-01,2018-03-31,2018-05-09 16:02:01+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15607000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q1,2018-01-01,2018-03-31,2018-05-09 16:02:01+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12418000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q1,2018-01-01,2018-03-31,2018-05-09 16:02:01+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-1006000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q1,2018-01-01,2018-03-31,2018-05-09 16:02:01+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1006000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q1,2018-01-01,2018-03-31,2018-05-09 16:02:01+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-13424000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q1,2018-01-01,2018-03-31,2018-05-09 16:02:01+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13424000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q1,2018-01-01,2018-03-31,2018-05-09 16:02:01+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13424000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q1,2018-01-01,2018-03-31,2018-05-09 16:02:01+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13424000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q1,2018-01-01,2018-03-31,2018-05-09 16:02:01+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,70700000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q1,2018-01-01,2018-03-31,2018-05-09 16:02:01+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.19
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q1,2018-01-01,2018-03-31,2018-05-09 16:02:01+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,70700000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q1,2018-01-01,2018-03-31,2018-05-09 16:02:01+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.19
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q1,2018-01-01,2018-03-31,2018-05-09 16:02:01+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,72517000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q1,2018-01-01,2018-03-31,2018-05-09 16:02:01+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.19
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q2,2018-04-01,2018-06-30,2018-07-31 17:15:27+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3878000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q2,2018-04-01,2018-06-30,2018-07-31 17:15:27+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3878000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q2,2018-04-01,2018-06-30,2018-07-31 17:15:27+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3878000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q2,2018-04-01,2018-06-30,2018-07-31 17:15:27+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7569000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q2,2018-04-01,2018-06-30,2018-07-31 17:15:27+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9347000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q2,2018-04-01,2018-06-30,2018-07-31 17:15:27+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,1300000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q2,2018-04-01,2018-06-30,2018-07-31 17:15:27+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18216000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q2,2018-04-01,2018-06-30,2018-07-31 17:15:27+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-14338000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q2,2018-04-01,2018-06-30,2018-07-31 17:15:27+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-930000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q2,2018-04-01,2018-06-30,2018-07-31 17:15:27+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-930000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q2,2018-04-01,2018-06-30,2018-07-31 17:15:27+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-15268000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q2,2018-04-01,2018-06-30,2018-07-31 17:15:27+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-96000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q2,2018-04-01,2018-06-30,2018-07-31 17:15:27+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-15172000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q2,2018-04-01,2018-06-30,2018-07-31 17:15:27+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-15172000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q2,2018-04-01,2018-06-30,2018-07-31 17:15:27+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-15172000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q2,2018-04-01,2018-06-30,2018-07-31 17:15:27+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,75900000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q2,2018-04-01,2018-06-30,2018-07-31 17:15:27+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.2
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q2,2018-04-01,2018-06-30,2018-07-31 17:15:27+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,75900000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q2,2018-04-01,2018-06-30,2018-07-31 17:15:27+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.2
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q2,2018-04-01,2018-06-30,2018-07-31 17:15:27+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,74017000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q2,2018-04-01,2018-06-30,2018-07-31 17:15:27+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.2
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 16:01:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5317000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 16:01:56+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5317000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 16:01:56+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5317000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 16:01:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7075000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 16:01:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8090000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 16:01:56+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,23200000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 16:01:56+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-8000000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 16:01:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,30365000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 16:01:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-25048000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 16:01:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-762000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 16:01:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-762000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 16:01:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-25810000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 16:01:56+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1453000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 16:01:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-24357000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 16:01:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-24357000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 16:01:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-24357000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 16:01:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,81200000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 16:01:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.3
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 16:01:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,81200000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 16:01:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.3
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 16:01:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,80325000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 16:01:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.3
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3238000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3238000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3238000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8090000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9600000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,100000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17790000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-14552000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-235000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-235000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-14787000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-83000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14704000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14704000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14704000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,77800000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.18
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,77800000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.18
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,77890000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.18
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:07:05+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4281000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:07:05+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4281000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:07:05+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:07:05+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4281000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:07:05+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9224000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:07:05+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12392000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:07:05+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,900000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:07:05+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,22516000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:07:05+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-18235000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:07:05+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-500000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:07:05+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-500000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:07:05+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-18735000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:07:05+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-18735000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:07:05+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-18735000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:07:05+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-18735000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:07:05+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,85200000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:07:05+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.22
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:07:05+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,85200000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:07:05+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.22
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:07:05+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,84542000.0
Progenics Pharmaceuticals Inc,PGNX,,0000835887,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:07:05+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.22
